Lukasz Michal Szafron

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7980362/publications.pdf

Version: 2024-02-01

25 papers 1,020 citations

643344 15 h-index 25 g-index

28 all docs

28 docs citations

times ranked

28

3158 citing authors

#	Article	IF	CITATIONS
1	Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature. PLoS ONE, 2022, 17, e0263980.	1.1	8
2	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
3	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.0	6
4	A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors. Biomolecules, 2021, 11, 1395.	1.8	3
5	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
6	Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis. Journal of Oncology, 2019, 2-13.	0.6	8
7	Clinical importance of <i>FANCD2, BRIP1, BRCA1, BRCA2</i> and <i>FANCF</i> expression in ovarian carcinomas. Cancer Biology and Therapy, 2019, 20, 843-854.	1.5	20
8	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	0.9	15
9	Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer. Oncotarget, 2018, 9, 17735-17755.	0.8	4
10	Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cellular Oncology (Dordrecht), 2017, 40, 529-536.	2.1	58
11	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
12	Prognosis of patients with BRCA1 -associated ovarian carcinomas depends on TP53 accumulation status in tumor cells. Gynecologic Oncology, 2017, 144, 369-376.	0.6	8
13	The calcium binding properties and structure prediction of the Hax-1 protein. Acta Biochimica Polonica, 2017, 64, 537-542.	0.3	7
14	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
15	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
16	The significance of c.690G>T polymorphism (rs34529039) and expression of the <i>CEBPA</i> gene in ovarian cancer outcome. Oncotarget, 2016, 7, 67412-67424.	0.8	17
17	The Novel Gene CRNDE Encodes a Nuclear Peptide (CRNDEP) Which Is Overexpressed in Highly Proliferating Tissues. PLoS ONE, 2015, 10, e0127475.	1.1	40
18	The putative oncogene, <i>CRNDE,</i> is a negative prognostic factor in ovarian cancer patients. Oncotarget, 2015, 6, 43897-43910.	0.8	51

#	Article	IF	CITATIONS
19	Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type. Orphanet Journal of Rare Diseases, 2015, 10, 32.	1.2	31
20	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
21	Risk of Ovarian Cancer and the NF-ήB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF1O</i> Cancer Research, 2014, 74, 852-861.	0.4	48
22	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
23	p19 ^{INK4d} mRNA and protein expression as new prognostic factors in ovarian cancer patients. Cancer Biology and Therapy, 2013, 14, 973-981.	1.5	11
24	High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genetics, 2012, 205, 94-100.	0.2	19
25	Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. Journal of Ovarian Research, 2011, 4, 20.	1.3	21